arrow
P

Peltan, Ithan

Utah System of Higher Education
H指数:0
被引数:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of immunization information systems, electronic medical records, and self-report to ascertain RSV vaccination status among US adults aged ≥60 years, 2023–2024

比较免疫接种信息系统、电子病历和自我报告以确定2023–2024年美国≥60岁成年人RSV疫苗接种状况

Vaccine
IF3.5
2025-11-220
PRE
Protocol and Statistical Analysis Plan for the Vasopressin for Septic Shock Pragmatic (VASSPR) Cluster-Crossover Randomized Trial

VASSPR集群交叉随机试验的方案与统计分析计划(VASSPR为Vasopressin for Septic Shock Pragmatic的缩写)

2025-11-011
OAAI
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus

成人呼吸道合胞病毒感染的多重共病模式与院内严重预后

2025-08-010
PRE
Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024

疫苗对流感A(H1N1)、A(H3N2)和B相关住院的效力,美国,2023年9月1日至2024年5月31日

2025-04-080
PRE
Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination

与呼吸道合胞病毒疫苗接种相关的患者层面和社区层面特征

2025-04-010
OA
COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United 2019-2022

2019-2022年美国住院成人中COVID-19和流感疫苗犹豫现象

VACCINE
IF3.5
2025-02-010
PRE
Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study

早期奥司他韦治疗对甲型流感住院成人患者的益处: 一项观察性研究

2024-11-281
OA
Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023

2022年9月-2023年8月,原始单价和二价新型冠状病毒肺炎疫苗对美国成人COVID-19-Associated住院和严重住院结局的有效性

2024-11-040
OA
Effectiveness and Safety of an Emergency Department Code Sepsis Protocol: A Pragmatic Clinical Trial
2024-11-010
PRE
Effectiveness of the Original Monovalent Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Against Hospitalization for COVID-19-Associated Venous Thromboembolism

原始单价信使RNA冠状病毒疾病2019 (新型冠状病毒肺炎) 疫苗接种系列对COVID-19-Associated静脉血栓栓塞住院的有效性

2024-10-150
PRE
Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024

更新的2023-2024 (单价XBB.1.5) 新型冠状病毒肺炎接种SARS-CoV-2 Omicron XBB和BA.2.86/JN.1的有效性谱系住院和临床严重程度的比较-IVY Network,26家医院,2023年10月18日-2024 3月9日

2024-08-069
OA
Methods of a cluster-randomized, type II hybrid implementation effectiveness trial to prospectively assess extended-duration thromboprophylaxis for at-risk medical patients being discharged to prevent hospital-associated venous thromboembolism
2024-08-010
OAAI
Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023

疫苗对甲型流感相关住院,器官衰竭和死亡的有效性: 美国,2022-2023

2023-12-0519
OA
Implementation of coordinated spontaneous awakening and breathing trials using telehealth-enabled, real-time audit and feedback for clinician adherence (TEACH): a type II hybrid effectiveness-implementation cluster-randomized trial

使用远程医疗,实时审计和临床医生依从性反馈 (TEACH) 实施协调的自发觉醒和呼吸试验: II型混合效果-实施集群随机试验

2023-09-212
OAAI